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Abstract 
Metabolic syndrome and cardiomyopathies are long-term consequences of chemo- and 
radiotherapy and develop long after completing the initial tumor treatment. The slow 
progression of such late effects might be an indication of the involvement of autoimmune 
processes in the development of such follow-up consequences. Functionally active autoanti-
bodies, which permanently stimulate relevant cell receptors, might be a crucial component. 
Here, we report the detection of functionally active agonistic autoantibodies such as the 
autoantibody against the adrenergic alpha1-receptor, the muscarinic M2-receptor, and the 
newly discovered autoantibody against the Mas-receptor in the plasma of a cancer survivor 
following chemotherapy treatment. 
Introduction 
The immune status of patients with tumors is a matter of intense investigation, with the 
aim to find appropriate markers for improving tumor diagnostics along with fundamental 
facts about tumor pathophysiology. This also holds true for the autoimmune situation [1, 2]. 
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The occurrence of autoantibodies might even be an early indicator of tumor development. 
However, to our knowledge, agonistic autoantibodies have not yet been the focus in this 
context. Thus, it is not known whether a tumor or the subsequent therapy could induce the 
formation of agonistic autoantibodies.  
As the name implies, agonistic autoantibodies activate receptors that are coupled with 
the G-protein signal cascade. The participation of such autoantibodies in the pathogenesis of 
a disease has been described for a variety of diseases that are often combined with vascular 
complications. This holds true for autoantibodies against the adrenergic beta1- and beta2 
receptors, adrenergic alpha1-receptor (alpha1-AAB), muscarinic M2-receptor (M2-AAB), 
AT1-receptor, endothelin receptor, and many more that are implicated in diseases such as 
malignant hypertension, dilated cardiomyopathy, Chagas’ cardiomyopathy, pulmonary 
hypertension, vascular necrotic kidney graft rejection, diabetes type 2, and others (excellent-
ly reviewed by Xia and Kellems [3]). The problem with these autoantibodies found at low 
titers is their potential to activate the corresponding receptors without inducing physiologi-
cally protective cell and tissue counterregulation responses such as the downregulation of 
the receptors. 
The reason for the occurrence of such autoantibodies is mostly unknown. Only in rare 
cases such as Chagas’ cardiomyopathy has the pathophysiological context been well 
investigated. Here, the autoantibodies are a consequence of biological mimicry after a 
parasite infection [4].  
With respect to the tumor situation, the tumor itself and, largely, drastic cell-destroying 
therapy such as chemotherapy and radiation are situations in which a nonphysiological 
amount of cell debris has to be cleared by the immune system. The subsequent induction of 
autoimmune reactions is very likely. We therefore searched for agonistic receptor autoanti-
bodies that have already been described for conditions that are similar to cardiomyopathy 
and metabolic syndrome caused by tumor therapy. 
Case Presentation 
A 57-year-old woman, who had previously undergone surgical carcinoma resection, 
received six cycles of adjuvant cisplatin/doxorubicin/paclitaxel treatment. After therapy, the 
patient suffered from diarrhea, polyneuropathy, and unregulated high blood pressure 
episodes that were mostly triggered by stress. 
Six months after chemotherapy, the M2-AAB, alpha1-AAB, and Mas-receptor autoanti-
body (Mas-AAB) were detected in the plasma (fig. 1). M2-AAB activity decreased 1 year after 
chemotherapy and was paralleled by an improvement in the unregulated bowel movements, 
and it disappeared 1.5 years after chemotherapy, again paralleled by a further improvement 
of the situation. 
Mas-AAB activity did not change over the 2-year observation period after chemothera-
py, while alpha1-AAB activity declined but did not disappear over the same period (fig. 1). 
Brief Description of the Measurement Method 
To detect the agonistic autoantibodies, a bioassay test system was applied that registers 
the change in the chronotropic activity of spontaneously beating neonatal rat cardiomyo-
cytes after the addition of the patient’s autoantibody containing the immunoglobulin fraction 
[5]. The autoantibodies target their receptors, inducing the corresponding change in the 
beating frequency (delta pulse rate/min, ΔPR/min) of the cells. In order to exclude falsified 
information caused by the combined occurrence of positive chronotropic autoantibodies 
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such as the alpha1-AAB and negative chronotropic autoantibodies such as the muscarinic 
M2-AAB, which would annihilate the signal, each autoantibody was measured while blocking 
the other. With respect to the combined occurrence of the alpha1-AAB and muscarinic M2-
AAB, atropine was added to block the signal of the muscarinic M2-AAB, while the addition of 
prazosin/urapidil enabled the measurement of the M2-AAB. For the detection and identifica-
tion of the Mas-AAB, a specific Mas-receptor antagonist (A779) was added to neutralize the 
chronotropic effect and verify the specificity.  
Discussion 
The development of long-term disturbances after chemotherapy, such as cardiomyopa-
thies (especially in the case of doxorubicin treatment [6, 7]) and the development of 
metabolic syndrome [8], is a sign of the slow progression of the respective disturbance and 
the potential involvement of autoimmune reactions. We therefore investigated the 
occurrence of agonistic autoantibodies after chemotherapy. 
Initially, one might think of autoantibodies that target intracellular structures, as is the 
case in lupus. However, Ersvaer et al. [9] found no evidence for such lupus autoantibodies 
after chemotherapy (ribosomal P autoantibodies). The same was not true for the agonistic 
autoantibodies against the G-protein coupled receptors, with the M2-AAB being detected in 
the reported case. The occurrence of the M2-AAB in chronic Chagas’ disease that develops 
into a megacolon is well accepted [10] and was considered a factor for the reported bowel 
movement problems observed in the reported case, especially since a relation between titer 
and the actual condition was observed. 
The participation of the alpha1-receptor AAB in hypertension and malignant hyperten-
sion is also a well-investigated fact [11]. The alpha1-receptor AAB, which has been detected 
in our patient, has also been reported to be present in a high percentage of patients with 
type 2 diabetes [12]. However, a direct relation between the occurrence of the alpha1-AAB 
and chemotherapy is not possible in this case. Blood pressure dysregulation began about 6–
7 months before tumor detection. The tumor-associated induction of the alpha1-AAB cannot 
be ruled out.  
The third AAB, Mas-AAB, has only recently been discovered in diabetic patients [Santos 
and Wallukat, unpubl. data] and is thought to interfere with blood pressure regulation since 
its target, the Mas-receptor, is an essential part of this regulatory system. The Mas-receptor 
is now a considered part of the novel axis of the renin system ACE2/angiotensin-(1–7)/Mas 
[13]. One of the main consequences of its activation is nitric oxide production in blood 
vessels and many other tissues [13]. Whether Mas-AAB could lead to nitric oxide production 
with consequent detrimental or beneficial effects remains to be clarified.  
In our case, the Mas-AAB was found 6 months after chemotherapy and persisted over 
the whole observation period of 2 years.  
When a high percentage of gonadal cancer survivors develop therapy-induced disturb-
ances such as metabolic syndrome [8], the possible role of therapy-induced specific agonistic 
autoantibodies as possible mediators should be considered and become the subject of 
systematic investigation. First, it should be determined whether tumor therapy or the tumor 
itself is the reason for the generation of agonistic autoantibodies. In the latter case, nobody 
would want to interfere with this system on the assumption that these autoantibodies are an 
essential part of the defense of the body against the tumor if they are more than the product 
of a ‘bystander effect’. Specific interference should only be considered when the agonistic 
autoantibodies are a clear side effect of tumor therapy and a cause of persistent side effects. 
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Since tumor survivors rely on an intact immune system as an essential prerequisite for 
relapse-free survival, nonspecific therapy such as the nonspecific removal of immunoglobu-
lins – as has been successfully applied in the treatment of autoantibody-associated 
cardiomyopathies [14] – should never be considered. However, recent and ongoing studies 
have been undertaken to develop highly specific blockers for single agonistic autoantibodies 
on, e.g., the aptamer basis [15], which would be a more appropriate tool for the tumor 
situation given that the autoantibodies against G-protein coupled receptors are a conse-
quence of therapy only. Before using such approaches, comprehensive studies clarifying all 
open questions will be necessary. 
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Fig. 1. Chronotropic activity (ΔPR/min) of the alpha1-AAB (filled circles), M2-AAB (filled triangles), and 
Mas-AAB (open circles) 6 months, about 1 year, and 2 years after chemotherapy (CM), respectively. 
 
